Overview

Neoadjuvant mFOLFOXIRI Chemotherapy Alone for Extramural Vascular Invasion Positive Locally Advanced Rectal Cancer

Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Extramural Vascular Invasion Positive(EMVI+) is a high risk of distant metastasis for locally advanced rectal cancer(LARC) after resection. The study is to evaluate the efficacy and safety of mFOLFOXIRI as neoadjuvant chemotherapy alone for EMVI+ LARC.
Phase:
Phase 2
Details
Lead Sponsor:
First Affiliated Hospital of Zhejiang University
Treatments:
Irinotecan
Oxaliplatin